http://www.i-base.info/htb/index.html Not-for-profit technical review of latest treatment research and news relating to clinical management of HIV. wed, 10 jun 2009 10:00:00 GMT wed, 10 jun 2009 10:00:00 GMT   en-gb HIV i-Base and contibutors rss@i-base.org.uk rss@i-base.org.uk   http://www.i-base.info/htb/v10/htb10-5-6/15th.htmll The annual BHIVA conferences consistently provide an opportunity to understand important aspects of HIV care, including the first presentations of results from national audits, lectures from international experts on emerging concerns and a wealth of studies from junior researchers.     http://www.i-base.info/htb/v10/htb10-5-6/Superinfection.html The rate and risk of reinfection with a second strain of HIV after primary infection are unclear with most instances reported as case studies. While reinfection clearly occurs, with viral load of the transmitting partner likely to be a significant risk factor, the clinical importance of a second infection, based on current limited data, appears largely related to acquisition of a resistant strain and its impact on reducing treatment options.   http://www.i-base.info/htb/v10/htb10-5-6/DEXA.html Short and colleagues presented results from using a portable DEXA scanner to identify high rates of reduced bone mineral density and relationship to ARV use in 168 HIV-positive men (median age 45) treated in Brighton. http://www.i-base.info/htb/v10/htb10-5-6/Assessing.html Peter Reiss summarised the growing number of studies on the relationship between abacavir and cardiovascular disease (CVD). [1] Four of six studies show an increased risk, while two, based on clinical trial data, do not.   http://www.i-base.info/htb/v10/htb10-5-6/Rapid.html In an oral presentation, Andrew Prendergast from Oxford University showed data from a study looking at the impact of cytomegalovirus (CMV) on HIV disease progression in a small group of South African infants.   http://www.i-base.info/htb/v10/htb10-5-6/Pharmacokinetic.html The World Health Organization (WHO) recommends ARV treatment for all HIV-infected infants less than 12 months old, and that this should be started as early as possible.   http://www.i-base.info/htb/v10/htb10-5-6/Pharmacokinetic.html The World Health Organization (WHO) recommends ARV treatment for all HIV-infected infants less than 12 months old, and that this should be started as early as possible.   http://www.i-base.info/htb/v10/htb10-5-6/10th.html The following early reports are included thanks to natap.org. Further coverage will be included in the next issue of HTB.   http://www.i-base.info/htb/v10/htb10-3-4/us.html Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.   http://www.i-base.info/htb/v10/htb10-5-6/How.html Protease inhibitors (PIs) fall into two groups - those whose concentration correlates closely with the boosting dose of ritonavir, and those that do not - according to a 16-study systematic analysis by Andrew Hill (University of Liverpool) and colleagues at other centers. http://www.i-base.info/htb/v10/htb10-5-6/Lopinavir.html On 6 April 2009, the US FDA approved changes to the product label for lopinavir/ritonavir (Kaletra) tablets and oral solution, reflecting new warnings and precautions regarding QT/QTC interval and PR interval prolongation information (electrical activity and rhythm of the heart). http://www.i-base.info/htb/v10/htb10-5-6/NA.html The following article was produced by the lead investigators in the START trial but has wider relevance for clinicians and patients following discussion about when to start treatment and the particular importance for data based on randomised studies.